Design issues in pivotal drug trials for drug sensitive tuberculosis (TB)
- 31 August 2008
- journal article
- research article
- Published by Elsevier BV in Tuberculosis
- Vol. 88, S85-S92
- https://doi.org/10.1016/s1472-9792(08)70039-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The ethics of non-inferiority trialsThe Lancet, 2008
- Non-inferiority trials are unethical because they disregard patients' interestsThe Lancet, 2007
- Proposal for Standardization of Optimized Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeat Typing ofMycobacterium tuberculosisJournal of Clinical Microbiology, 2006
- Reinfection and Mixed Infection Cause Changing Mycobacterium tuberculosis Drug-Resistance PatternsAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Rate of Reinfection Tuberculosis after Successful Treatment Is Higher than Rate of New TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Evaluation of the Bactec 960 Automated Nonradiometric System for Isolation of Mycobacteria from Clinical SpecimensEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000
- Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final reportTubercle, 1986
- Whither short-course chemotherapy?Respiratory Medicine, 1981
- Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: The results up to 30 monthsTubercle, 1981
- Tuberculosis in Kenya: Follow-up of the second (1974) national sampling survey and a comparison with the follow-up data from the first (1964) national sampling surveyTubercle, 1979